



CGA M-15—2018
STANDARD FOR
APPROPRIATE AND
EFFECTIVE REGULATIONS
FOR MEDICAL GASES
WITHIN 21 CFR PARTS 201,
205, AND 210/211

THIRD EDITION

PLEASE NOTE:

The information contained in this document was obtained from sources believed to be reliable and is based on technical information and experience currently available from members of the Compressed Gas Association, Inc. and others. However, the Association or its members, jointly or severally, make no guarantee of the results and assume no liability or responsibility in connection with the information or suggestions herein contained. Moreover, it should not be assumed that every acceptable commodity grade, test or safety procedure or method, precaution, equipment or device is contained within, or that abnormal or unusual circumstances may not warrant or suggest further requirements or additional procedure.

This document is subject to periodic review, and users are cautioned to obtain the latest edition. The Association invites comments and suggestions for consideration. In connection with such review, any such comments or suggestions will be fully reviewed by the Association after giving the party, upon request, a reasonable opportunity to be heard. Proposed changes may be submitted via the Internet at our web site, www.cganet.com.

This document should not be confused with federal, state, provincial, or municipal specifications or regulations; insurance requirements; or national safety codes. While the Association recommends reference to or use of this document by government agencies and others, this document is purely voluntary and not binding unless adopted by reference in regulations.

A listing of all publications, audiovisual programs, safety and technical bulletins, and safety posters is available via the Internet at our website at www.cganet.com. For more information contact CGA at Phone: 703-788-2700, ext. 799. E-mail: customerservice@cganet.com.

Work Item 24-003
Medical Gases Committee

THIRD EDITION: 2018
SECOND EDITION: 2017
FIRST EDITION: 2014

© 2018 The Compressed Gas Association, Inc. All rights reserved.

All materials contained in this work are protected by United States and international copyright laws. No part of this work may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopying, recording, or any information storage and retrieval system without permission in writing from The Compressed Gas Association, Inc. All requests for permission to reproduce material from this work should be directed to The Compressed Gas Association, Inc., 8484 Westpark Drive, Suite 220, McLean, VA 22102. You may not alter or remove any trademark, copyright or other notice from this work.

Contents	Page
Introduction	1
Title 21—Food and Drugs, Chapter I—Food and Drug Administration, Department of Health and Human Services Subchapter C—Drugs: General	1
Part 201 Labeling	1
Subpart A—General Labeling Provisions	1
§ 201.1 Drugs; name and place of business of manufacturer, packer, or distributor.	1
§ 201.10 Drugs; statement of ingredients.....	3
§ 201.18 Drugs; significance of control numbers.	5
Subpart B—Labeling Requirements for Prescription Drugs and/or Insulin	5
§ 201.51 Declaration of net quantity of contents.	5
§ 201.56 Requirements on content and format of labeling for human prescription drug and biological products.	6
Subpart D—Exemptions from Adequate Directions for Use.....	10
§ 201.100 Prescription drugs for human use.....	10
§ 201.105 Veterinary drugs.	12
§ 201.128 Meaning of “intended uses”.	14
Subpart E—Other Exemptions	14
§ 201.161 Medical gases.....	14
§ 201.328 Labeling of medical gas containers.	15
Title 21—Food and Drugs, Chapter I—Food and Drug Administration, Department of Health and Human Services, Subchapter C—Drugs: General	17
Part 205 Guidelines for State Licensing of Wholesale Prescription Drug Distributors	17
§ 205.1 Scope.	17
§ 205.2 Purpose.	17
§ 205.3 Definitions.....	17
§ 205.4 Wholesale drug distributor licensing requirement.....	18
§ 205.5 Minimum required information for licensure.	18
§ 205.6 Minimum qualifications.	19
§ 205.7 Personnel.	19
§ 205.8 Violations and penalties.....	19
§ 205.50 Minimum requirements for the storage and handling of prescription drugs and for the establishment and maintenance of prescription drug distribution records.	20
Title 21—Food and Drugs, Chapter I—Food and Drug Administration, Department of Health and Human Services, Subchapter C—Drugs: General	23
Part 210 Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General	23
§ 210.1 Status of current good manufacturing practice regulations.	23
§ 210.2 Applicability of current good manufacturing practice regulations.	23
§ 210.3 Definitions.....	24
Title 21—Food and Drugs Chapter I—Food and Drug Administration Department of Health and Human Services Subchapter C—Drugs: General	26
Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals.....	26
Subpart A—General Provisions	26
§ 211.1 Scope.	26
§ 211.3 Definitions.....	26
Subpart B—Organization and Personnel	26
§ 211.22 Responsibilities of quality control unit.....	26
§ 211.25 Personnel qualifications.....	27
§ 211.28 Personnel responsibilities.....	27
§ 211.34 Consultants.....	27
Subpart C—Buildings and Facilities	27
§ 211.42 Design and construction features.	27

§ 211.44 Lighting	28
§ 211.46 Ventilation, air filtration, air heating and cooling	28
Subpart D—Equipment	30
§ 211.63 Equipment design, size, and location	30
§ 211.65 Equipment construction	30
§ 211.67 Equipment cleaning and maintenance	30
§ 211.68 Automatic, mechanical, and electronic equipment	31
§ 211.72 Filters	31
Subpart E—Control of Components and Drug Product Containers and Closures	31
§ 211.80 General requirements	31
§ 211.82 Receipt and storage of untested components, drug product containers, and closures	32
§ 211.84 Testing and approval or rejection of components, drug product containers, and closures. ...	32
§ 211.85 Testing and approval or rejection of designated medical gas components, containers, and closures	33
§ 211.86 Use of approved components, drug product containers, and closures	34
§ 211.87 Retesting of approved components, drug product containers, and closures	34
§ 211.89 Rejected components, drug product containers, and closures	34
§ 211.94 Drug product containers and closures	34
Subpart F—Production and Process Controls	35
§ 211.100 Written procedures; deviations	35
§ 211.101 Charge-in of components	35
§ 211.103 Calculation of yield	36
§ 211.105 Equipment identification	36
§ 211.110 Sampling and testing of in-process materials and drug products	36
§ 211.111 Time limitations on production	37
§ 211.113 Control of microbiological contamination	37
§ 211.115 Reprocessing	37
Subpart G—Packaging and Labeling Control	37
§ 211.122 Materials examination and usage criteria	37
§ 211.125 Labeling issuance	38
§ 211.130 Packaging and labeling operations	39
§ 211.132 Tamper-evident packaging requirements for over-the-counter (OTC) human drug products	39
§ 211.134 Drug product inspection	41
§ 211.137 Expiration dating	41
Subpart H—Holding and Distribution	41
§ 211.142 Warehousing procedures	41
§ 211.150 Distribution procedures	42
Subpart I—Laboratory Controls	42
§ 211.160 General requirements	42
§ 211.165 Testing and release for distribution	42
§ 211.166 Stability testing	43
§ 211.167 Special testing requirements	44
§ 211.170 Reserve Samples	44
§ 211.173 Laboratory animals	45
§ 211.176 Penicillin contamination	45
Subpart J—Records and Reports	45
§ 211.180 General requirements	45
§ 211.182 Equipment cleaning and use log	46
§ 211.184 Component, drug product container, closure, and labeling records	46
§ 211.186 Master production and control records	46
§ 211.188 Batch production and control records	47
§ 211.189 Production and control records for designated medical gases	48
§ 211.192 Production record review	49
§ 211.194 Laboratory records	49
§ 211.196 Distribution records	50
§ 211.198 Complaint files	50

Subpart K—Returned and Salvaged Drug Products 51
 § 211.204 Returned drug products 51
 § 211.208 Drug product salvaging 51
References 52

Introduction

This standard reflects the Compressed Gas Association's (CGA) consensus position for how the Federal Food and Drug Administration's (FDA) regulations for finished pharmaceuticals found in Title 21 of the U.S. *Code of Federal Regulations* (21 CFR) Parts 201 (labeling), 205 (wholesale distribution), and 210 and 211 (GMPs), should be revised for designated medical gases or combinations thereof. This standard is consistent with established and long standing industry practice yielding safe and efficacious designated medical gases and consistent with the Congressional intent in the *Food and Drug Administration Safety and Innovation Act's* (FDASIA) identifying the need for revisions to 21 CFR [1, 2].¹

For 21 CFR Part 201 only those subparts and sections where CGA has submitted proposed modifications to the FDA for designated medical gases and combinations thereof are included below. For 21 CFR Parts 205, 210, and 211, all subparts and sections are reproduced in this standard in their entirety with CGA's proposed modifications for designated medical gases and combinations thereof.

NOTE—CGA's modifications to the regulations identify new text with underlines and deleted text with strikeouts.

Title 21—Food and Drugs, Chapter I—Food and Drug Administration, Department of Health and Human Services Subchapter C—Drugs: General

Part 201 Labeling

NOTE—Only includes those subparts and sections with proposed changes for designated medical gases and combinations thereof.

Subpart A—General Labeling Provisions

§ 201.1 Drugs; name and place of business of manufacturer, packer, or distributor.

- (a) A drug or drug product (as defined in §320.1 of this chapter) in finished package form is misbranded under section 502 (a) and (b)(1) of the act if its label does not bear conspicuously the name and place of business of the manufacturer, packer, or distributor. This paragraph does not apply to any drug or drug product dispensed in accordance with section 503(b)(1) of the act.
- (b) As used in this section, and for purposes of section 502 (a) and (b)(1) of the act, the manufacturer of a drug product is the person who performs all of the following operations that are required to produce the product: (1) Mixing, (2) granulating, (3) milling, (4) molding, (5) lyophilizing, (6) tableting, (7) encapsulating, (8) coating, (9) sterilizing, and (10) filling sterile, aerosol, or gaseous drugs into dispensing containers, and (11) filling designated medical gases or combinations thereof into containers by any of the following processes: (a) liquid to liquid, (b) liquid to gas, or (c) gas to gas.
- (c) If no person performs all of the applicable operations listed in paragraph (b) of this section, no person may be represented as manufacturer except as follows:
 - (1) If the person performs more than one half of the applicable operations listed in paragraph (b) of this section and acknowledges the contribution of other persons who have performed the remaining applicable operations by stating on the product label that "Certain manufacturing operations have been performed by other firms."; or
 - (2) If the person performs at least one applicable operation listed in paragraph (b) of this section and identifies by appropriate designation all other persons who have performed the remaining applicable operations, e.g., "Made by (Person A), Filled by (Person B), Sterilized by (Person C)"; or

¹ References are shown by bracketed numbers and are listed in order of appearance in the reference section.